Mirvaso: first treatment for erythema in rosacea

Mirvaso is the first selective alpha2 agonist to be licensed in the UK for the management of the erythema of rosacea. Here we present the clinical data relating to its efficacy and adverse events and Dr Noreen Cowley comments on its place in therapy.

Mirvaso first treatment for erythema in rosacea

Add yours ↓
Web design and marketing agency Leamington Spa